See the DrugPatentWatch profile for tigecycline

Tigecycline is an antibiotic often used to treat various bacterial infections. However, its effectiveness in mixed therapies has been a topic of interest in the medical community. According to a study published in the Journal of Antimicrobial Chemotherapy, tigecycline, when used in combination with other antibiotics, has shown promising results in treating severe infections caused by drug-resistant bacteria [1].

The study analyzed the clinical outcomes of 52 patients with mixed infections who received tigecycline-based combination therapy. The results indicated that the therapy was successful in 73.1% of the cases, suggesting that tigecycline can be an effective option in mixed therapies.

However, it is important to note that tigecycline has been associated with certain adverse effects, such as nausea, vomiting, and diarrhea [2]. Therefore, its use should be carefully considered and balanced against the potential benefits.

In addition, it is crucial to consider the potential for antibiotic resistance when using tigecycline in combination therapies. According to DrugPatentWatch.com, tigecycline's patent expired in 2018, which may lead to increased use and potential overuse of the drug, increasing the risk of antibiotic resistance [3].

In conclusion, tigecycline has shown to be successful in mixed therapies in 73.1% of cases, according to a study of 52 patients. However, its use should be carefully considered due to potential adverse effects and the risk of antibiotic resistance.

Sources:
[1] <https://academic.oup.com/jac/article/65/11/2355/2538747>
[2] <https://www.ncbi.nlm.nih.gov/books/NBK138331/>
[3] <https://www.drugpatentwatch.com/drugs/tigecycline>